SRDX

Surmodics Inc

Add to Watchlist

Advanced Chart

29.200

+0.390(+1.350%)

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

29.230

Open

28.720

VWAP

29.00

Vol

66.17K

Mkt Cap

417.54M

Low

28.370

Amount

1.92M

EV/EBITDA(TTM)

90.58

Total Shares

14.26M

408.87M

EV/OCF(TTM)

P/S(TTM)

3.36

Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

29.68M

-0.8%

-0.145

+262.5%

29.09M

-12.47%

-0.183

+41.02%

28.04M

-7.59%

-0.193

-28.4%

Estimates Revision

The market is revising Downward the revenue expectations for Surmodics, Inc. (SRDX) for FY2025, with the revenue forecasts being adjusted by -12.52% over the past three months. During the same period, the stock price has changed by -11.14%.

Revenue Estimates for FY2025

Revise Downward

-12.52%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+213.2%

In Past 3 Month

Stock Price

Go Down

-11.14%

In Past 3 Month

3 Analyst Rating

47.26% Upside

Wall Street analysts forecast SRDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRDX is 43.00 USD with a low forecast of 43.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

47.26% Upside

Current: 29.200

Low

43.00

Averages

43.00

High

43.00

47.26% Upside

Current: 29.200

Low

43.00

Averages

43.00

High

43.00

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-30

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-30

Reiterates

Hold

Reason

Lake Street

Brooks O'Neil

Hold

Strong Buy

Upgrades

$43

2025-03-07

Reason

Lake Street

Brooks O'Neil

Price Target

$43

2025-03-07

Upgrades

Hold

Strong Buy

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-01-30

Reason

Needham

Mike Matson

Price Target

n/a

2025-01-30

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2024-11-07

Reason

Needham

Mike Matson

Price Target

n/a

2024-11-07

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2024-08-05

Reason

Needham

Mike Matson

Price Target

n/a

2024-08-05

Reiterates

Hold

Reason

Barrington Research

Michael Petusky

Buy

Hold

Downgrades

n/a

2024-05-30

Reason

Barrington Research

Michael Petusky

Price Target

n/a

2024-05-30

Downgrades

Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Surmodics Inc (SRDX.O) is -50.43, compared to its 5-year average forward P/E of 666.94. For a more detailed relative valuation and DCF analysis to assess Surmodics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

666.94

Current PE

-50.43

Overvalued PE

3630.09

Undervalued PE

-2296.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

26.73

Current EV/EBITDA

43.67

Overvalued EV/EBITDA

89.30

Undervalued EV/EBITDA

-35.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.71

Current PS

3.43

Overvalued PS

6.14

Undervalued PS

3.27